DistantNews
Support us
New autoimmune neurological disease treatments offer hope for remission
🇬🇷 Greece /Health & Science

New autoimmune neurological disease treatments offer hope for remission

From Ta Nea · () Greek

Translated from Greek, summarized and contextualized by DistantNews.

At a glance

News Named sources Context piece
  • Rapid advancements in neuroimmunology are transforming treatment approaches for autoimmune neurological diseases.
  • Innovative therapies like monoclonal antibodies and CAR-T cells show promising results, even leading to remission in rare cases.
  • These developments offer new hope for patients with conditions such as multiple sclerosis, myasthenia gravis, and Stiff Person syndrome.

Neuroimmunology is experiencing rapid and significant advancements, with new knowledge about immune and inflammatory processes in neurological and neuromuscular diseases revolutionizing treatment.

There is a truly impressive research activity. Today, with the help of artificial intelligence, many processes are significantly accelerated. There are new therapeutic approaches, either new antibodies or the so-called CAR-T cells, which are already widely used in oncology.

— Nikos GrigoriadisProfessor of Neurology at the Aristotle University of Thessaloniki, discussing advancements in neuroimmunology.

Recent breakthroughs are generating substantial expectations for managing severe autoimmune neurological conditions through innovative therapies, including monoclonal antibodies and CAR-T cell treatments. Professor of Neurology at the Aristotle University of Thessaloniki (AUTH), Nikos Grigoriadis, highlighted these developments in an interview with the Athens-Macedonian News Agency (AMNA) during the International Symposium on Interdisciplinary Approaches to Neurological Disorders (ISMIND 2026) in Thessaloniki.

"There is truly impressive research activity. Today, with the help of artificial intelligence, many processes are significantly accelerated. There are new therapeutic approaches, either new antibodies or the so-called CAR-T cells, which are already widely used in oncology," Grigoriadis stated. He explained that these sensitized T lymphocytes target specific types of cancer cells or other cells and have been tested in cases of severe myasthenia gravis, multiple sclerosis, and Stiff Person syndrome, a rare and difficult neurological disorder.

These therapies have already been tested in cases of severe myasthenia gravis, multiple sclerosis, and Stiff Person syndrome, a rare and particularly difficult neurological disorder. Many clinical studies are ongoing. No one can yet speak with absolute certainty and draw firm conclusions, but the indications are truly hopeful.

— Nikos GrigoriadisExplaining the application and early results of CAR-T cell therapy for neurological conditions.

"Many clinical studies are ongoing. No one can yet speak with absolute certainty and draw firm conclusions, but the indications are truly hopeful. Especially for Stiff Person syndrome, which is a rare but particularly severe autoimmune neuroimmunological syndrome where the patient experiences intense muscle stiffness and painful spasms throughout the body. In some cases, patients were completely freed from their disease. CAR-T cells were tested in this syndrome, and remission was observed. These are truly impressive results," Grigoriadis noted.

Especially for Stiff Person syndrome, which is a rare but particularly severe autoimmune neuroimmunological syndrome where the patient experiences intense muscle stiffness and painful spasms throughout the body. In some cases, patients were completely freed from their disease. CAR-T cells were tested in this syndrome, and remission was observed. These are truly impressive results.

— Nikos GrigoriadisHighlighting the remarkable outcomes of CAR-T cell therapy in treating Stiff Person syndrome.

For more common conditions like multiple sclerosis or myasthenia gravis, new treatments are expected soon with defined administration criteria. The same applies to other demyelinating diseases, such as neuromyelitis optica. "Today, there are therapies that in many cases can control the disease 100%. What once seemed like fiction is now a reality. Some of these therapies completely control disease activity, like monoclonal antibodies against complement in the case of neuromyelitis optica. Others control disease activity. Today, the picture observed in multiple sclerosis is nothing like the multiple sclerosis we knew," Grigoriadis concluded.

Today, there are therapies that in many cases can control the disease 100%. What once seemed like fiction is now a reality.

— Nikos GrigoriadisComparing current treatment capabilities for neurological diseases with past limitations.
DistantNews Editorial

Originally published by Ta Nea in Greek. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog